Does the Inclusion of CD34+  B-cell Progenitors (Hematogones) in Stem Cell Enumeration of Apheresis Product Using ISHAGE Protocol Affect the Final Harvest dose Adequacy and the Outcome of Transplantation? A Single Institution Experience from Southern India

ConclusionThe inclusion of hematogones in CD34+  HSC enumeration of apheresis products did not yield any impact on neither the final dose nor the outcome of transplant in this study. However, it is recommended to exclude them from the final count when they are>  10% of the final HSC lest it overestimate the final harvest dose and outcome of HSCT.
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research